Open AccessSafety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study
Author(s) -
Toussaint Rouamba,
Houreratou Barry,
Espérance Ouédraogo,
Marc Christian Tahita,
Nobila Valentin Yaméogo,
Armel Poda,
Arnaud Eric Diendéré,
Abdoul–Salam Ouédraogo,
Innocent Valéa,
Amariane M Koné,
Cherileila Thiombiano,
Isidore Traoré,
Zékiba Tarnagda,
Serge Aimé Sawadogo,
Zakaria Gansané,
Yibar Kambiré,
Idrissa Sanou,
F. Barro-Traoré,
Maxime Drabo,
Halidou Tinto
Publication year - 2021
Publication title -
therapeutics and clinical risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.719
H-Index - 55
eISSN - 1178-203X
pISSN - 1176-6336
DOI - 10.2147/tcrm.s330813
Subject(s) - medicine , hydroxychloroquine , chloroquine , azithromycin , palpitations , adverse effect , prospective cohort study , rash , observational study , cohort study , covid-19 , disease , malaria , pathology , infectious disease (medical specialty) , microbiology and biotechnology , biology , antibiotics
Though chloroquine derivatives are used in the treatment of coronavirus disease 2019 (COVID-19) in many countries worldwide, doubts remain about the safety and efficacy of these drugs, especially in African communities where published data are scarce.